Paolo Tarantino/X
Jul 11, 2025, 18:40
Paolo Tarantino: A Recap of the Epic Journey of HER2 as a Biomarker Over the Past 30 years
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared on X about a recent paper by Marko Velimirovic and Jame Abraham published in JCO Oncology Practice:
“Wonderful editorial by Marko Velimirovic and Jame Abraham accompanying our JCO Oncology Practice review on the evolution of HER2 testing in oncology.
Recommend reading to anyone interested in a recap of the epic journey of HER2 as a biomarker over the past 30 years.”
Title: Human Epidermal Growth Factor Receptor 2 Positivity a Moving Target in the Era of Antibody-Drug Conjugates
Journal: JCO Oncology Practice
Authors: Marko Velimirovic, Jame Abraham
More posts featuring Paolo Tarantino on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 11, 2025, 18:04
Jul 11, 2025, 17:27
Jul 11, 2025, 17:17
Jul 11, 2025, 16:54